WallStreetZenWallStreetZen

NYSEMKT: PLX
Protalix Biotherapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

PLX past revenue growth

How has PLX's revenue growth performed historically?
Company
37.48%
Industry
144.63%
Market
17.55%
PLX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PLX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PLX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PLX earnings and revenue history

Current Revenue
$65.5M
Current Earnings
$8.3M
Current Profit Margin
12.7%

PLX Return on Equity

Current Company
29.7%
Current Industry
-63.5%
Current Market
188%
PLX's Return on Equity (29.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PLX announces earnings.

PLX Return on Assets

Current Company
10.2%
Current Industry
2.9%
PLX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PLX Return on Capital Employed

Current Company
26.89%
Current Industry
19.5%
PLX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PLX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PLX$65.49M$11.65M$8.31M+13.85%N/A
RVPH$0.00-$39.24M-$39.26MN/AN/A
LPTX$0.00-$81.40M-$81.41M-100.00%N/A
ALRN$0.00-$15.61M-$15.73MN/AN/A
BYSI$1.55MN/A-$27.51M+34.56%N/A
View Top Biotech Stocks

PLX earnings dates

Next earnings date
Jun 27, 2024

Protalix Biotherapeutics Earnings & Revenue FAQ

What were PLX's earnings last quarter?

On Invalid Date, Protalix Biotherapeutics (NYSEMKT: PLX) reported Q4 2023 earnings per share (EPS) of -$0.10, up 42.86% year over year. Total Protalix Biotherapeutics earnings for the quarter were -$6.04 million. In the same quarter last year, Protalix Biotherapeutics's earnings per share (EPS) was -$0.07.

If you're new to stock investing, here's how to buy Protalix Biotherapeutics stock.

What was PLX's earnings growth in the past year?

As of Q2 2024, Protalix Biotherapeutics's earnings has grown year over year. Protalix Biotherapeutics's earnings in the past year totalled $8.31 million.

What is PLX's earnings date?

Protalix Biotherapeutics's earnings date is Invalid Date. Add PLX to your watchlist to be reminded of PLX's next earnings announcement.

What was PLX's revenue last quarter?

On Invalid Date, Protalix Biotherapeutics (NYSEMKT: PLX) reported Q4 2023 revenue of $10.49 million up 21.69% year over year. In the same quarter last year, Protalix Biotherapeutics's revenue was $8.62 million.

What was PLX's revenue growth in the past year?

As of Q2 2024, Protalix Biotherapeutics's revenue has grown 37.48% year over year. This is 107.15 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Protalix Biotherapeutics's revenue in the past year totalled $65.49 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.